streptokinase in acute pulmonary embolism

Phase 2

• Conditions: Acute Pulmonary Embolism.; Pulmonary heart disease and diseases of pulmonary circulation; I26, I27,

• Registration Number: IRCT201104245625N2
• Lead Sponsor: Vice Chancellor for research,Tehran Heart Center (TUMS)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

streptokinase only begin for massive or submassive pulmonary emboli patients who have these conditions:
unstable hemodynamic (systolic blood pressure less than 90 mmHg or reduce systolic blood pressure more 40 mmhg)
intermediate or sever RV dysfunction(right ventricle)
Exclusion criteria:
history of hemorrhagic stroke or unknown origin stroke;Ischemic stroke in past 6 months;central nervous system neoplasm;
major trauma,head surgery or injury in past 3 months;TIA attack in past 6 months;oral anticoagulant drugs users;pregnancy or 1st post partum week;traumatic resuscitation;resistant hypertension(systolic blood pressure more than180 mmHg);progressive liver disease;infected endocarditis;active stomach ulcer;

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pulmonary artery pressure(PAP). Timepoint: before begining of streptokinase and 24-72h after treatment begining. Method of measurement: Echocardiography.